Search Results

Home → Flash News → New Episode Alert! 🎙️ Ep. 163 of the Dr. GPCR Podcast is here! 🚀 This time, we sit down with Dr. Dmitry Veprintsev to discuss the importance of asking the right GPCR questions. Whether you're a researcher, student, or GPCR enthusiast, this episode is packed with insights that will challenge how you think about your experiments. ✳️Tune in at https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-163-with-dr.-dmitry- #DrGPCR #GPCRPodcast #Pharmacology #DrugDiscovery #Biotech #GPCRs Published on April 1, 2025 Category Dr. GPCR Podcast New Episode Alert! 🎙️ Ep. 163 of the Dr. GPCR Podcast is here! 🚀 This time, we sit down with Dr. Dmitry Veprintsev to discuss the importance of asking the right GPCR questions. Whether you're a researcher, student, or GPCR enthusiast, this episode is packed with insights that will challenge how you think about your experiments. ✳️Tune in at https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-163-with-dr.-dmitry- #DrGPCR #GPCRPodcast #Pharmacology #DrugDiscovery #Biotech #GPCRs Previous Next Recent Articles

Awkward... This page isn’t available. Go Home

Awkward... This page isn’t available. Go Home

Awkward... This page isn’t available. Go Home

Awkward... This page isn’t available. Go Home

Awkward... This page isn’t available. Go Home

Awkward... This page isn’t available. Go Home

Awkward... This page isn’t available. Go Home

Awkward... This page isn’t available. Go Home

Awkward... This page isn’t available. Go Home

Awkward... This page isn’t available. Go Home

Awkward... This page isn’t available. Go Home

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Interrogating Multiscale Receptors Functions in Space Date & Time Saturday, November 4th / 10:35 AM Abstract Coming Soon About Martin Beaulieu Dr. Beaulieu received a Ph.D. in Neurological Sciences from McGill University and completed his post-doctoral training at Duke University. Prior to his recruitment Dr. Beaulieu was an associate professor and Canada Research Chair (Tier2) in the Department of Psychiatry and Neuroscience at Laval University. Dr. Beaulieu’s research is aimed at understanding how cellular and molecular mechanisms regulated by psychoactive drugs intersect with genetic risk factors for mental illnesses such as schizophrenia, depression, and bipolar disorder. Dr. Beaulieu has pioneered work establishing a role for Beta-arrestin signaling in the brain in vivo and has established its importance in D2 dopamine receptors (D2R) functions. These receptors belong to the super-family of G-protein coupled receptors (GPCR), the major molecular target for drug development. In particular, D2R is the main pharmacological target of antipsychotic drugs prescribed for schizophrenia and bipolar disorders. Work by the Beaulieu Lab has demonstrated that mood stabilizer drugs (e.g. lithium) used for bipolar disorder therapy target signaling mechanisms regulated by dopamine receptors, thus providing a framework to understand how different drug classes can engage overlapping cellular mechanisms to exert their action. The Beaulieu group is presently investigating how cell surface express proteins can act as allosteric modulators of D2R signaling and explores the potential usefulness of beta-arrestins for the development of new pharmaceutical agents. Translational validation is important to validate findings obtained from experimental models research and bridge the gap between bench and bedside. Working in collaboration with geneticists, the Beaulieu-Lab has identified interactions between cellular mechanisms engaged by D2R and psychiatric drugs with genetic risk factors implicated in schizophrenia by large whole-genome association studies (GWAS) in humans. These investigations have led to the identification of an RNA binding protein (FXR1P) involved in the regulation of protein synthesis as a potential downstream effector of the action of mood stabilizers and other psychoactive drugs. In addition to basic research, the Beaulieu group is also actively implicated in translational research and industry collaboration to develop new drugs and drug development technology. Martin Beaulieu on the web University of Toronto Google Scholar LinkedIn ResearchGate Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Closing remarks < Previous Session Next Session >

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda State of the Art Talk Adhesion GPCR in Mechanobiology Abstract Only Available for AGPCR24 Attendees About Tobias Langenhan "1997-2004: Medical school and Dr. med. Neuroanatomy (Würzburg, Germany); 2004-2005: M.Sc . Neuroscience (Oxford, UK); 2005-2009: D.Phil. Neuroscience (Oxford, UK); 2009-2016: Group leader, Institute of Neurophysiology (Würzburg, Germany); 2016: Heisenberg professorship (Würzburg, Germany); 2016-to date: Professor and Chair in Biochemistry (Leipzig, Germany)" Tobias Langenhan on the web Langenhan Lab LinkedIn < Previous Session Next Session >

Home → Flash News → ep 169 with sokhom pin some 1 Published on July 8, 2025 Category Dr. GPCR Podcast Redefine what a PhD path can look like. Sokhom S. Pin didn’t quit his job, pause his career, or sacrifice family time. He built a PhD program inside BMS—while working full-time and raising three kids. Industry-based research. Employer-funded. Custom-built for impact. 🎧 Ep. 169 is available now: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-169-with-dr-sokhom-pin #GPCRtraining #GPCRscientistnetwork #DrGPCR #nontraditionalPhD #GPCR #DrGPCR Previous Next Recent Articles

Celtarys partners with Dr. GPCR to expand fluorescent ligand tools for GPCR drug discovery, connecting biotech startups and scientists worldwide. Home → Flash News → ⚠️ Registration Deadline today! This is your last chance to register for Principles of Pharmacology II - Advanced Methods for the Optimization of Candidate Selection with Dr. Terry Kenakin. Learn more about new ligands and new GPCR behaviors that produce unique drug profiles. Published on October 15, 2024 Category Dr. GPCR Courses ⚠️ Registration Deadline today! This is your last chance to register for Principles of Pharmacology II - Advanced Methods for the Optimization of Candidate Selection with Dr. Terry Kenakin. Learn more about new ligands and new GPCR behaviors that produce unique drug profiles. ✳️ Last chance!!! https://www.ecosystem.drgpcr.com/advanced-methods-for-the-optimization-of-candidate-selection #gpcr #drgpcr Previous Next Recent Articles

Discover how low-offset kinetics reshape drug efficacy. Join Terry’s Corner and master irreversible pharmacology for modern discovery programs. Home → Flash News → irreversible drugs post 1 Irreversible Drugs – Trailer Published on October 21, 2025 Category Terry's Corner Irreversible drugs change the rules of engagement. Unlike reversible ligands, their impact can persist long after the compound is gone — creating durable pharmacological effects that reshape how pharmacokinetics and pharmacodynamics intersect. In modern discovery programs, that’s a decisive advantage (or a hidden liability) in candidate selection. In this week’s lesson, you’ll unpack: Why low offset rates can mimic covalent effects without forming actual bonds. How target depletion and replenishment kinetics define the therapeutic window. How persistent binding alters structured tissue penetration — and why that matters for tumor targeting and beyond. These tactical frameworks are used to optimize molecules, sharpen PK/PD strategy, and mitigate downstream safety surprises before they appear in IND-enabling studies. Understanding irreversible interactions can mean the difference between a stalled program and a strategic breakthrough. Those who master kinetic pharmacology set the pace. 🟢 Join Terry’s Corner and sharpen your pharmacology toolkit. ✳️ Terry's Corner | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #DrugDiscovery #MedicinalChemistry #PKPD #ReceptorKinetics #DrugDevelopment Previous Next Recent Articles

Home → Flash News → GPCRs regulate key biological processes, but how exactly do inhibitory Gαi proteins control signal transduction beyond adenylyl cyclase suppression? New research sheds light on these pathways! ✨ Want to learn more? Did you know that we work hard to bring you the most recent GPCR News, weekly? Catch up today in the Ecosystem using your free site membership! Published on October 22, 2024 Category GPCR Weekly News GPCRs regulate key biological processes, but how exactly do inhibitory Gαi proteins control signal transduction beyond adenylyl cyclase suppression? New research sheds light on these pathways! ✨ Want to learn more? Did you know that we work hard to bring you the most recent GPCR News, weekly? Catch up today in the Ecosystem using your free site membership! ➡️ https:// www.ecosystem.drgpcr.com/receptor-activation-and-signaling/germline-mutations-in-a-g-protein-identify-signaling-cross-talk-in-t-cells #GPCR #DrGPCR Previous Next Recent Articles

Home → Flash News → Class B GPCR drugs are reshaping treatment for migraine, diabetes, and obesity- but did you know ligand bias plays a key role in their success? This new review explores how tweaking peptide drugs can boost efficacy, reduce side effects, and unlock next-gen therapies. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️https://www.ecosystem.drgpcr.com/reviews/where-are-we-now%3F-biased-signalling-of-class-b-g-protein-coupled-receptor-targeted-therapeutics #gpcr#drgpcr Published on June 2, 2025 Category GPCR Weekly News Class B GPCR drugs are reshaping treatment for migraine, diabetes, and obesity- but did you know ligand bias plays a key role in their success? This new review explores how tweaking peptide drugs can boost efficacy, reduce side effects, and unlock next-gen therapies. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️ https://www.ecosystem.drgpcr.com/reviews/where-are-we-now%3F-biased-signalling-of-class-b-g-protein-coupled-receptor-targeted-therapeutics #gpcr#drgpcr Previous Next Recent Articles

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Registration & Coffee with light breakfast < Previous Session Next Session >

Dr. Michelle Halls reveals how organized GPCR signaling drives assay innovation and new therapeutic insights. << Back to podcast list Dr. GPCR Podcast Strategic Partners Leadership, Impact, and GPCR Signaling with Dr. Michelle Halls In this episode Dr.Michelle Halls shares how dissecting the spatial organization of GPCR signaling opens new doors in drug discovery. From early discoveries in cyclic AMP signaling to uncovering ultrasensitive receptor responses at femtomolar ligand concentrations, her work highlights why receptor localization and protein complex assembly matter for therapeutic targeting. This conversation is especially valuable for scientists developing functional assays, fluorescence-based tools, and high-throughput GPCR screens. ⸻ Inside This Episode How ultrasensitive GPCR signaling emerges from pre-assembled receptor–effector complexes at the plasma membrane. Why receptor localization and scaffolding dramatically shift functional readouts in disease models. What early cyclic AMP assays revealed about spatial signaling long before high-content technologies existed. The moment when femtomolar ligand concentrations uncovered unexpected receptor sensitivity. How an integrated training and lab structure at Monash Institute of Pharmaceutical Sciences fosters innovation in functional assay development and GPCR research. ⸻ Why It Might Hit Home If you’ve ever: Faced unexpected assay behavior at ultra-low ligand concentrations, Balanced innovation with robust validation under real experimental constraints, Tried to map signaling heterogeneity in disease-relevant models, Built assays that need to work in real biology—not just on paper, …this episode will resonate. ⸻ About the Guest Michelle Halls is an Associate Professor at Monash University and Deputy Theme Leader of Drug Discovery Biology at Monash Institute of Pharmaceutical Sciences. She leads the Spatial Organisation of Signalling Laboratory, where her team investigates how GPCRs orchestrate localized signaling events, how these mechanisms are hijacked in disease, and how they can be leveraged for therapeutic innovation. Michelle earned her PhD in Molecular Pharmacology at Monash University, then trained in single-cell biology as an NHMRC CJ Martin Fellow at University of Cambridge. She established her lab in 2011, and today she is a Viertel Senior Medical Research Fellow. Her recognitions include the 2024 ASCEPT Achievement Award, the 2023 BPS Geoffrey Burnstock Prize, and the 2019 Faculty Future Research Leader Award. ⸻ More about Michelle Halls Monash Institute of Pharmaceutical Sciences Bluesky LinkedIn ⸻ Articles about this Podcast Episode How GPCR Spatial Signaling Sparked a Scientific Journey From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Collaboration Built an Innovation Engine ⸻ 🎓 Want more like this? Get behind-the-scenes conversations, advanced assay development strategies, and practical GPCR tools inside Dr. GPCR Premium . Join a global GPCR community of scientists and biotech leaders. 👉 Join now Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Antonella Di Pizio About this episode In this episode of the Dr. GPCR podcast , we meet with Dr. Antonella Di Pizio, an independent research group leader at the Leibniz Institute for Food Systems Biology at the Technical University of Munich. Antonella trained as a medicinal chemist in Italy, followed by a Ph.D. in computational medicinal chemistry, during which she developed a taste for structural biology. Antonella then moved to Israel, where she first started working on bitter taste GPCRs in Dr. Masha Niv's lab . Today, Antonella has expanded her research to olfactory GPCRs and trace amine receptors. Join us to learn more about chemosensory GPCRs and how computational pharmacology can help better understand their function. Dr. Antonella Di Pizio on the web Leibniz-Institute for Food Systems Biology at the Technical University of Munich Google Scholar PubMed LinkedIn Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Yamina Berchiche About this episode GPCRs have played a central role in my scientific career ever since I took Dr. Michel Bouvier’s class as an undergraduate student at the University of Montreal in early 2000. During the past 2 decades, my research mainly focused on chemokine receptor structure/function relationships. For the purposes of this presentation, I will walk you through my various career experiences and include the skills I learned during each experience, which ultimately led me to found Dr. GPCR. Last, I will give an overview of the various programs we established at Dr. GPCR, present our team as well as provide you with a sneak peek of our future podcast guests and more. I gave a talk on October 12th at the 3rd ERNEST meeting about the Dr.GPCR Ecosystem . I want to say thank you to the ERNEST meeting organizers for the invitation with special thanks to Dr. Martha Summer and Dr. Alexander Hauser , and Luise Wagner . For more information about the ERNEST network, visit https://ernest-gpcr.eu/ . Dr. Yamina Berchiche on the web D r. GPCR Ecosystem Member Website LinkedIn Publications Twitter Facebook Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Marta Filizola About Dr. Marta Filizola Dr. Marta Filizola is the Sharon & Frederick A. Klingenstein-Nathan G. Kase, MD Professor in the Departments of Pharmacological Sciences, Neuroscience, and Artificial Intelligence and Human Health, as well as the Dean of The Graduate School of Biomedical Sciences at the Icahn School of Medicine at Mount Sinai, in New York, USA. The overall goal of her research program is to obtain rigorous mechanistic insights into the structure, dynamics, and function of important classes of membrane proteins and prominent drug targets, including G protein-coupled receptors (GPCRs), transporters, channels, and 3 integrins. To this end, her lab uses several computational structural biology tools and rational drug design approaches, ranging from molecular modeling, bioinformatics, cheminformatics, molecular dynamics simulations, free-energy perturbations, machine learning, etc. A native of Italy, she received her Bachelor’s and Master’s degrees in Chemistry from the University Federico II in Naples. She pursued a Ph.D. in Computational Chemistry at the Second University of Naples and a postdoctorate in Computational Biophysics at the Molecular Research Institute in California, USA. Dr. Marta Filizola on the web Icahn School of Medicine at Mount Sinai Filizola Lab Wikipedia Twitter Linkedin ResearchGate Google Scholar Orcid PubMed Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Graciela Pineyro About this episode Dr. Graciela Pineyro’s love for GPCR pharmacology started in Uruguay where she first worked on the serotonin receptors. This interest in research and pharmacology took Graciela to Canada where she stayed ever since she arrived for her Ph.D. work. Graciela has done extensive work on the molecular pharmacology of opioid receptors, exploring their signaling, trafficking, and their ability to activate different signaling pathways and signaling bias. Today, Graciela and her team’s efforts are directed towards the characterization of the pharmacological properties of cannabinoids in conjunction with terpenes for pain relief. Dr. Graciela Pineyro on the web Dr. Graciela Pineyro on LinkedIn Dr. Graciela Pineyro - University of Montreal Dr. Graciela Pineyro - CHU Ste-Justine Research Centre Pineyro Lab Publications on Google Scholar Pineyro Lab on Pubmed Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Oliver Hartley About Dr. Oliver Hartley Oliver Hartley is VP for Drug Discovery at Orion Biotechnology . He is the inventor of OB-002 as well as the key technology underlying Orion’s discovery platform. Trained as a biochemist, he completed a PhD in protein engineering (Cambridge, UK) with Sir Gregory Winter (Nobel Prize for Chemistry, 2018). Since then Oliver has worked at the University of Geneva, where his research on peptide engineering and GPCR pharmacology has led to a series of high-profile publications and new intellectual property, and at the Mintaka Foundation for Medical Research with a role as co-founder and Chief Scientific Officer. Dr. Oliver Hartley on the web LinkedIn Orion Biotechnology Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule G Proteins and GPCRs in Cancer: Novel Precision Targeted and Immunotherapies Date & Time Friday, November 3rd / 3:30 PM Abstract Coming Soon About J. Silvio Gutkind "Dr. Gutkind is a Distinguished Professor and Chair of the Department of Pharmacology, School of Medicine, and Associate Director for Basic Science at the Moores Cancer Center, University of California San Diego (UCSD). He served as Branch Chief at NIDCR, NIH, since 1998 until his recruitment to UCSD in 2015. His research team has pioneered the study of G proteins and G protein coupled receptors (GPCRs) in human malignancies. He is exploiting the emerging information on dysregulated signaling circuitries and individual genomic and molecular alterations to develop new precision cancer treatments, and to identify novel multimodal strategies to enhance the response to cancer immunotherapies." J. Silvio Gutkind on the web Gutkind Lab – UC San Diego Moores Cancer Center Gutkind Lab publications Pubmed LinkedIn Twitter UCSD Moores Cancer Center Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Lukas Grätz About Dr. Lukas Grätz "After a BSc in biology and a MSc in bioinformatics, I have been working in David Gloriam's group as a bioinformatician. My initial focus was on creating an automated chimeric homology modeling pipeline for GPCRs and since have branched out to multiple areas of GPCR research such as sequence alignments, generic numbering systems, structure data, G protein and arrestin coupling and more. As a developer, and more recently the lead developer of GPCRdb my day-to-day work centers around the maintenance and resource/tool development of GPCRdb and its sister databases. I am also affiliated with György Keserű's group at the RCNS in Hungary. I lived in Denmark, Poland, now I live in Hungary. I am married, I have two daughters. In my free time I like to play the guitar, sing and play board games. " Dr. Lukas Grätz on the web Karolinska Institutet ResearchGate PubMed Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Nicola J. Smith About Dr. Nicola J. Smith Dr. Nicola J Smith is an expert in molecular pharmacology with a track record in exploring GPCR structure-function relationships in the context of cardiovascular disease and metabolic disorders. She is a National Heart Foundation of Australia Future Leader Fellow and runs a laboratory of 7 Ph.D. and Honours students at UNSW Sydney, where she has recently been promoted to Associate Professor. Most recently, Dr. Smith’s team has made advances in the understanding of how an orphan GPCR exerts its effects both in vitro (cell culture and ex vivo models) and in vivo (measures of physiological and pathological cardiometabolic function in unconscious and conscious mice). Together with Irina Kufareva , UCSD, her team developed a novel approach to identifying ligands for orphan GPCRs by developing a powerful new computational tool for identifying ‘surrogate’ ligands (borrowed from other receptors) for orphan GPCRs, named GPCR-CoINPocket. Her career goal is to leverage this expertise to establish a research program that takes orphan GPCRs from ‘locked’, inaccessible receptors to well-characterized and understood ‘unlocked’ therapeutic targets with high-affinity ligands. Dr. Nicola J. Smith on the web UNSW Sydney LinkedIn Retraction Watch Twitter Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>